Preview

User

Not a user? Register with this site Forgot your password?

Problems of Endocrinology

Advanced search

Endogenous hypercorticism as a prothrombogenic state

https://doi.org/10.14341/probl20125813-8

Abstract

The patients in the active phase of endogenous hypercorticism not infrequently present with hypercoagulation syndrome characterized by abnormal blood clotting in conjunction with slowed fibrinolysis, elevated fibrinogen and D-dimer concentrations. In addition, such patients exhibit endotheliosis manifest as a rise in the PAI-1 and Willebrand factor levels. The remission of the Cushing's disease (CD) is associated with a higher fibrinogen, thrombomodulin, endothelin-1, and D-dimer levels compared with CD patients in the active phase of this disease and healthy subjects (control). This suggests the continuing progression of endotheliosis, enhanced thrombogenicity, and the increased risk of cardiovascular complications.

References

1. Гончаров Н.П., Колесникова Г.С, Тодуа Т.Н., Рожинская Л.Я., Марова Е.И. Стероидогенез в коре надпочечников и секреция надпочечниковых андрогенов при болезни и синдроме Иценко-Кушинга. Проблемы эндокринологии 2007; 53: 1: 26-29.

2. Долгов В.В., Свирин П.В. Лабораторная диагностика нарушений гемостаза. М-Тверь:Триада 2005; 44-49, 59-64.

3. Лупинская З.А. Эндотелий сосудов - основной регулятор местного кровотока. Вестник КРСУ 2003; 7.

4. Марова Е.И., Арапова С.Д., Бельченко Л.В. Болезнь Иценко-Кушинга. Методическое пособие для врачей. М 2000.

5. Мелкумян А.Л., Морозов К.М. и др. Факторы риска системы гемостаза при заболеваниях аорты, магистральных и периферических сосудов. Методическое пособие для врачей. М 2001.

6. Петрищев Н.Н., Власов Т.Д., Капитонова О.А. Эндотелиальная дисфункция и методы ее коррекции. Материалы Ассамблеи "Врач-Провизор-Пациент" 2003; 57.

7. Петрищев Н.Н., Власов Т.Д. Физиология и патофизиология эндотелия. Сборник статей. Дисфункция эндотелия. Причины, механизмы, фармакологическая коррекция. Под ред. Н.Н. Петрищева. М 2003; 4-38.

8. Суханова Г.А. Тромбофилии как фактор развития тромботических состояний. В кн.: Очерки по производственной и клинической трансфузиологии. Под ред. А.И. Воробьева. М: Ньюдиамед ;364-372.

9. Суханова Г.А., Рудакова В.Е., Васильев С.А. Профилактика тромбоэмболических осложнений у лиц среднего и пожилого возраста. Клин геронтол 2007; 4: 10-15.

10. Шиффман Ф.Дж. Патофизиология системы крови. Под ред. Ю.В. Наточина. СПб: Невский диалект 2001; 191-214, 253-269.

11. Akaza I., Yoshimoto T., Tsuchiya К., Hirata Y. Endothelial Dysfunction Associated with Hypercortisolism is Reversible in Cushing's Syndrome. Endocr J 2009.

12. Alessi M.C., Juhan-Vague I. Contribution of PAI-1 in cardiovascular pathology. Arch Mal Coeur Vaiss 2004; 97: 6: 673-678.

13. Ambrosi B., Sartorio A., Pizzocaro A., Passini E., Bottasso B., Federici A. Evaluation of haemostatic and fibrinolytic markers in patients with Cushing's syndrome and in patients with adrenal incidentaloma. Exp Clin Endocrinol Diabet 2000; 108: 4: 294-298.

14. Arnaldi G., Mancini Т., Polenta В., Boscara M. Cardiovascular risk in Cushing's syndrom. Pituitary 2004; 7: 253-256.

15. Boscaro M., Sonino N., Scarda A., Barzon L., Fallo F., Sartori M.T., Patrassi G.M., Girolami A. Anticoagulant prophylaxis markedly reduces thromboembolic complications in Cushing's syndrome. J Clin Endocrinol Metab 2002; 87: 8: 3662-3666.

16. Brotman D.J., Girod J.P., Garcia M.J. et al. Effects of short-term glucocorticoids on cardiovascular biomarkers. J Clin Endocrin Metab 2005; 90: 3202-3208.

17. Casonato A., Daidone V., Sartorello F., Albiger N., Romualdi C., Mantero F., Pagnan A., Scaroni С. Polymorphisms in von Willebrand factor gene promoter influence the glucocorticoid-induced increase in von Willebrand factor: the lesson learned from Cushing syndrome. Br J Haematol 2008; 140: 2: 230-235.

18. Colao A., Pivonello R., Spiezia S., Faggiano A., Ferone D., Filippella M., Marzullo P., Cerbone G., Siciliani M., Lombardi G. Persistence of increased cardiovascular risk in patients with Cushing's disease after five years of successful cure. J Clin Endocrinol Metab 1999; 84: 8: 2664-2672.

19. Dover A.R., Hadoke P.W., Walker B.R., Newby D.E. Acute effects of glucocorticoids on endothelial fibrinolytic and vasodilator function in humans. J Cardiovasc Pharmacol 2007; 50: 3: 321-326.

20. Erbil Y., Ademoğlu E., Ozbey N., Barbaras U., Yanik В.Т., Salmaslioglu A., Bozbora A., Ozarmağan S. Evaluation of the cardiovascular risk in patients with subclinical Cushing syndrome before and after surgery. World J Surg 2006; 30: 9: 1665-1667.

21. Erem C., Nuhoglu I., Yilmaz M., Kocak M., Demirel A., Ucuncu O., Onder Ersoz H. Blood coagulation and fibrinolysis in patients with Cushing's syndrome: increased plasminogen activator inhibitor-1, decreased tissue factor pathway inhibitor, and unchanged thrombin-activatable fibrinolysis inhibitor levels. J Endocrinol Invest 2009; 32: 2: 169-174.

22. Extabe J., Vazquez J.A. Morbidity and mortality in Cushing's disease: an epidemiological approach. Clin Endocrinol (Oxf) 1994; 40: 479-484.

23. Faggiano A., Pivonello R., Spiezia S., De Martino M.C., Filippella M., Di Somma C., Lombardi G., Colao A. Cardiovascular risk factors and common carotid artery caliber and stiffness in patients with Cushing's disease during active disease and 1 year after disease remission. J Clin Endocrinol Metab 2003; 88: 6: 2527-2533.

24. Fatti L.M., Bottasso B., Invitti C., Coppola R., Cavagnini F., Mannucci P.M. Markers of activation of coagulation and fibrinolysis in patients with Cushing's syndrome. J Endocrinol Invest 2000; 23: 3: 145-150.

25. Jacoby R.C., Owings J.T, Ortega T. et al. Biochemical basis for hypercoagulable state seen in Cushing syndrome; discussion 1006-1007. Arch Surg 2001; 136: 9: 1003-1006.

26. Jezkova J., Marek J., Prazny M., Krsek M., Malickova K., Rosicka M., Jarkovska Z., Pecen L. Effect of hypercortisolism on development of atherosclerotic changes in blood vessels. Vnitr Lek 2003; 49: 8: 656-667.

27. Johansson L., Jansson J.H., Boman K., Nilsson T.K., Stegmayr B., Hallmans G. Tissue plasminogen activator, plasminogen activator inhibitor-1, and tissue plasminogen activator/plasminogen activator inhibitor-1 complex as risk factors for the development of a first stroke. Stroke 2000; 31: 1: 26-32.

28. Juhan-Vague I., Morange P., Alessi C.M. Fibrinolytic function and coronary risk. Curr Cardiol Rep 1999; 1: 2: 119-124.

29. Kastelan D., Dusek T., Kraljevic I., Polasek O., Giljevic Z., Solak M., Salek S.Z., Jelcic J., Aganovic I., Korsic M. Hypercoagulability in Cushing's syndrome: the role of specific haemostatic and fibrinolytic markers. Endocrine 2009; 36: l: 70-74.

30. Kirilov G., Tomova A., Dakovska L., Kumanov P., Shinkov A., Alexandrov A.S. Elevated plasma endothelin as an additional cardiovascular risk factor in patients with Cushing's syndrome. Eur J Endocrinol 2003; 149: 6: 549-553.

31. Kristo C., Ueland T., Godang K., Aukrust P., Bollerslev J. Biochemical markers for cardiovascular risk following treatment in endogenous Cushing's syndrome. J Endocrinol Invest 2008; 31: 5: 400-405.

32. La Brocca A., Terzolo M., Pia A., Paccotti P., De Giulli P., Angeli A. Reccurent thromboembolism as a hallmark of Cushing's syndrome. J Endocrinol Invest 1997; 20: 4: 211-214.

33. Lindholm J., Juul S. et al. Incidence and late prognosis of Cushing's syndrome: a population-based study. J Clin Endocrinol Metab 2001; 86: 1: 117-123.

34. Mancini T., Kola B., Mantero F., Boscaro M., Arnaldi G. High cardiovascular risk in patients with Cushing's syndrome according to 1999 WHO/ISH guidelines. Clin Endocrinol (Oxf) 2004; 61: 6: 768-777.

35. Manetti L., Bogazzi F., Giovannetti C., Raffaelli V., Genovesi M., Pellegrini G., Ruocco L., Iannelli A., Martino E. Changes in coagulation indexes and occurrence of venous thromboembolism in patients with Cushing's syndrome:' results from a prospective study before and after surgery. Department of Endocrinology, University of Pisa, Ospedale Cisanello. Eur J Endocrinol 2010; 163: 5: 783-791.

36. Patrassi G.M., Sartori M.T., Viero M.L., Scarano L., Boscaro M., Girolami A. The fibrinolytic potential in patients with Cushing's disease: a clue to their hypercoagulable state. Blood Coagul Fibrinolysis 1992; 3: 6: 789-793.

37. Pivonello R., De Martino M.C., De Leo M., Tauchmanová L., Faggiano A., Lombardi G., Colao A. Cushing's syndrome: aftermath of the cure. Arq Bras Endocrinol Metabol 2007; 51: 8: 1381-1391.

38. Prázný M., Jezková J., Horová E., Lázarová V., Hána V., Kvasnicka J., Pecen L., Marek J., Skrha J., Krsek M. Impaired microvascular reactivity and endothelial function in patients with Cushing's syndrome: influence of arterial hypertension. Physiol Res 2008; 57: l: 13-22.

39. Trementino L., Arnaldi G., Appolloni G., Daidone V., Scaroni C., Casonato A., Boscaro M. Coagulopathy in Cushing's Syndrome. Neuroendocrinology 2010; 92: Suppl 1: 55-59.

40. Van Zaane B., Nur E., Squizzato A., Dekkers O.M., Twickler M.T., Fliers E., Gerdes V.E., Biiller H.R., Brandjes D.P. Hypercoagulable state in Cushing's syndrome: a systematic review. J Clin Endocrinol Metab 2009; 94: 8: 2743-2750.

41. Verhamme P., Hoylaerts M.F. The pivotal role of the endothelium in haemostasis and thrombosis. Acta Clin Belg 2006; 61: 5: 213-219.

42. Vaughan D.E. PAI-1 and atherothrombosis. J Thromb Haemost 2005; 3: 8: 1879-1883.

43. Wang T.J., Gona P., Larson M.G., Toiler G.H., Levy D., Newton-Cheh C., Jacques P.F., Rifai N., Selhub J., Robins S.J., Benjamin E.J., D'Agostino R.B., Vasan R.S. Multiple biomarkers for the prediction of first major cardiovascular events and death. N Engl J Med 2006; 355: 25: 2631-2639.

44. Weisel J.W. Fibrinogen and fibrin. Adv Protein Chem 2005; 70: 247-299.

45. Whitworth J.A., Williamson P.M., Mangos G., Kelly J.J. Cardiovascular consequences of cortisol excess. Vasc Health Risk Manag 2005; 1: 4: 291-299.

46. Whitworth J.A., Mangos G.J., Kelly J.J. Cushing, cortisol, and cardiovascular disease. Hypertension 2000; 36: 912-916.

47. Wiman B., Andersson T., Hallqvist J., Reuterwall C., Ahlbom A., deFaire U. Plasma levels of tissue plasminogen activator/plasminogen activator inhibitor-1 complex and von Willebrand factor are significant risk markers for recurrent myocardial infarction in the Stockholm Heart Epidemiology Program (SHEEP) study. Arterioscler Thromb Vasc Biol 2000; 20: 8: 2019-2023.

48. Yang C.Y., Chou C.W., Lin M.B., Wang L.W., Chen S.Y., Cheng H.M. Reccurent pulmonary embolism in an with Cushing's syndrome, adrenocortical adenoma, pheochromocytoma and prostate adenocarcinoma. J Clin Med Ass 2004; 67: 7: 360-365.

49. Younge P.A., Wiles P.G., Shmidt D. Cushing's syndrome: still a potential killing disease. J R Soc Med 1995; 88: 174-175.

50. Zacharieva S., Atanassova I., Nachev E., Orbetzova M., Kirilov G., Kalinov K., Shigarminova R. Markers of vascular function in hypertension due to Cushing's syndrome. Horm Metab Res 2005; 37: l: 36-39.


Review

For citations:

Khodakova I.V., Rozhinskaia L.I., Sukhanova G.A., Arapova S.D., Il'in A.V., Chirkova L.D. Endogenous hypercorticism as a prothrombogenic state. Problems of Endocrinology. 2012;58(1):3-8. https://doi.org/10.14341/probl20125813-8

Views: 641


ISSN 0375-9660 (Print)
ISSN 2308-1430 (Online)

11, Dm. Ul’yanova str., Moscow, Russian Federation, 117292

Processing of personal data
supported by NEICON (Elpub lab)